Serono Adds Newron Parkinson's Disease Agent Safinamide With Licensing Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III studies are investigating safinamide as an add-on therapy to dopamine agonists in early Parkinson's disease patients.